Basic information Description Clinical research Precautions References Safety Related Supplier

Empagliflozin

Product NameEmpagliflozin

CAS864070-44-0

MFC23H27ClO7

MW450.91

EINECS620-176-8

MOL File864070-44-0.mol

Chemical Properties

Boiling point 665℃
Density  1.398
Flash point 356℃
storage temp.  2-8°C
pka 13.23±0.70(Predicted)

Empagliflozin(trade name Jardiance) is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated in urine. On August 1, 2014, the Food and Drug Administration (FDA) officially approved the drug for the treatment of type 2 diabetes, to improve and control blood glucose of adults. Empagliflozin is the third SGLT-2 inhibiting drugs approved by FDA. Another two SGLT-2 inhibitor drugs, canagliflozin and dapagliflozin, belonging to Johnson Pharmaceuticals, AstraZeneca and Bristol-Myers Squibb respectively, are approved by FDA in November 2013 and January 2014 respectively.

Usage And Synthesis

Empagliflozin Supplier

Empagliflozin manufacturers

Related articles